Cardiff Oncology, Inc. filings document regulatory disclosures for a clinical-stage oncology company developing onvansertib and PLK1-inhibition programs. Recent Form 8-K reports cover financial results, business updates, Regulation FD presentation materials, CRDF-004 clinical disclosures in first-line RAS-mutated metastatic colorectal cancer and other material events tied to the company's development strategy.
The company's proxy and current reports also address board and executive governance, officer appointments and departures, separation agreements, compensation arrangements, equity awards and Nasdaq inducement grants. These filings include formal disclosure of risk themes common to clinical-stage biotechnology issuers, including clinical-trial uncertainty, financing needs, dependence on key personnel and operating disruptions.
Cardiff Oncology, Inc. lists Leila Alland, its Chief Medical Officer, as a reporting person in a Form 3.
Cardiff Oncology, Inc. appointed Dr. Leila Alland as interim Chief Medical Officer after Dr. Roger Sidhu separated from the company on October 22, 2026, in a mutually agreed transition. The consulting agreement with Leila Alland Md Consultancy LLC began October 23, 2026 and runs until the earlier of April 22, 2027 or completion of services; the parties may extend it by mutual agreement. It provides for a monthly fee of $35,000, and Dr. Alland will devote up to 50% of her professional time to the role.
Cardiff said its randomized Phase 2 trial in first-line RAS-mutated metastatic colorectal cancer remains ongoing. Median PFS has not been reached in the onvansertib 30 mg plus FOLFIRI and bevacizumab arm, and all patients remaining on trial have been on treatment for more than 18 months.
Cardiff Oncology, Inc. (CRDF) stockholders approved an amendment to increase authorized capital stock from 170,000,000 to 320,000,000 shares and authorized common stock from 150,000,000 to 300,000,000 shares.
At the October 22, 2026 Special Meeting, 48,084,246 common shares were represented, constituting a quorum. The proposal received 37,675,355 votes for, 10,125,739 against, 283,147 abstentions and 5 broker non-votes.
Cardiff Oncology, Inc. (CRDF) disclosed that on September 14, 2026 it entered into a Confidential Settlement Agreement and Release with Nerviano Medical Sciences to resolve litigation related to their 2017 exclusive license covering onvansertib. The parties agreed to a full mutual release of claims, dismissal of the case with prejudice, no admission of liability, and no monetary payment by either side.
Contemporaneously, the companies signed an Amendment to the License Agreement that will become effective once the litigation is dismissed. Key changes include an updated exclusivity framework preventing Nerviano and its affiliates from clinically developing or commercializing competing products or onvansertib during the royalty term (subject to exceptions), a revised royalty and additional license fee structure tied to annual net sales, new development milestones and potential performance-related payments for Cardiff’s planned Phase 3 program, and revised post‑termination royalty tiers payable by Nerviano to Cardiff. The amendment also gives Nerviano a board observer seat and a seat on Cardiff’s Scientific Advisory Board, strengthens joint governance and reporting provisions for onvansertib’s development, revises assignment economics in change‑of‑control scenarios before Phase 3 readout, and requires a judicial or arbitral determination of material breach before termination for cause.
Cardiff Oncology, Inc. (CRDF) is asking stockholders at a special meeting on October 22, 2026 to approve an amendment to its Amended and Restated Certificate of Incorporation to increase authorized capital stock from 170,000,000 to 320,000,000 shares and authorized common stock from 150,000,000 to 300,000,000. Authorized preferred stock remains 20,000,000 shares.
The board states this increase is intended to provide flexibility for future uses, including potential partnerships, acquisitions, financings (such as offerings under a $400 million universal shelf registration and a $150 million Open Market Sale Agreement with Jefferies), equity incentive plans, and other corporate purposes. As of August 26, 2026, there were 77,795,249 common shares outstanding, plus additional shares reserved or issuable under warrants, options, equity plans and preferred stock.
Cardiff notes that issuing additional shares could dilute earnings per share and existing stockholders’ equity and voting rights, and could make a change of control more difficult, while stating the proposal is not being made as an anti-takeover measure. A second proposal would allow adjournment of the meeting to solicit more proxies if there are insufficient votes to approve the amendment.
Cardiff Oncology, Inc. is asking stockholders at a special meeting in October 2026 to approve an amendment to its Amended and Restated Certificate of Incorporation to increase authorized capital stock from 170,000,000 to 320,000,000 shares, including an increase in authorized common stock from 150,000,000 to 300,000,000 shares, while keeping authorized preferred stock at 20,000,000 shares. The additional common shares would have the same rights as existing common stock and could be issued for financings, strategic transactions, equity incentives, warrant exercises, and other corporate purposes, including potential use under an existing $400 million universal shelf registration and a $150 million at-the-market offering program with Jefferies LLC.
The company notes that issuing additional common stock in the future could dilute existing stockholders’ ownership and voting power and could affect the trading price of the shares, though no specific new issuances are currently planned beyond existing agreements and plans. A second proposal would authorize adjournment of the special meeting, if needed, to solicit additional proxies in support of the share increase. The board of directors unanimously recommends voting “FOR” both proposals.
Cardiff Oncology, Inc. reported continued operating losses while progressing its lead PLK1 inhibitor, onvansertib, through Phase 2 development in RAS-mutated metastatic colorectal cancer and other investigator-initiated trials. For the quarter ended June 30, 2026, royalty revenue was $104,000 and net loss was $9.2 million, compared with $13.9 million a year earlier, as research and development expenses fell to $5.9 million from $11.6 million due to trial completions and reduced preclinical work.
For the first six months of 2026, net loss was $21.6 million and operating cash outflows were $24.1 million. As of June 30, 2026, Cardiff held $34.5 million in cash, cash equivalents and short-term investments and disclosed that this is not sufficient to meet funding requirements for at least 12 months after issuance, leading management to conclude there is substantial doubt about its ability to continue as a going concern. Subsequent to quarter-end, the company raised $10.1 million in gross proceeds via a registered direct offering of common stock and warrants. Cardiff also highlighted ongoing litigation with its onvansertib licensor NMS regarding alleged termination of the license agreement, noting that an adverse outcome could materially impact its business.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Cardiff Oncology, Inc. common stock. BlackRock reports beneficial ownership of 863,259 shares of common stock, representing 1.3% of the class as of the reporting date.
BlackRock has sole voting power and sole dispositive power over all 863,259 shares, with no shared voting or dispositive power. The filing notes that various underlying clients have economic interests in these shares, but no single person has more than 5% of Cardiff Oncology’s outstanding common stock.
Cardiff Oncology, Inc. director Gary W. Pace reported open-market purchases dated 2026-07-14 of 687,285 shares of common stock at $1.455 per share and 687,285 common stock purchase warrants with an exercise price of $1.33 per share. Following these transactions he holds 2,043,661 common shares directly plus 687,285 warrants. The warrants become exercisable on the later of six months after issuance or the “Authorized Share Increase Date” and remain exercisable for five and one-half years after that Initial Exercise Date.